HCV dispute blamed for Murex' loss
This article was originally published in Clinica
Murex has reported a net loss of $2.1 million in the third quarter ended September 30th, 1995, compared with a net income of $1.5 million in the same period last year. The Canadian company blames the continuing HCV patent dispute with Chiron. Because of the litigation, Murex has moved its HCV production site twice - to Italy and more recently to Morocco. Problems associated with this final move resulted in a $1.1 million loss in HCV sales, says Murex.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.